To evaluate the prognostic value of genetic mutations for acute myeloid leukemia (AML) patients, we examined the gene status for both fusion products such as AML1 Multivariate analysis identified DNMT3A and MLL mutations as independent factors predicting inferior overall survival (OS) and event free survival (EFS), while bi-allelic CEBPA mutations or NPM1 mutations without DNMT3A mutations conferred a better OS and EFS in either the whole group or among younger patients aged less than 60 years. The use of molecular markers allows us to subdivide the series of 605 cases into distinct prognostic groups with potential clinical relevance.
Introduction
Acute myeloid leukemia (AML) is a group of heterogeneous diseases, with considerable diversities in terms of clinical behavior and prognosis. [1] [2] [3] [4] [5] Clinical and genetic prognostic markers are now crucial in evaluation of AML patients and guiding rational management. Among them, cytogenetic abnormalities are considered as the most important prognostic factors of AML. [5] [6] [7] [8] [9] [10] [11] For example, acute promyelocytic leukemia (APL, AML-M3) with t(15;17) translocation is associated with a favorable prognosis [12] [13] [14] , and core binding factor (CBF) leukemias with t(8;21) translocation in AML-M2 variant (M2v) or inv(16) rearrangement in AML-M4 with eosinophilia (M4eo) have also been reported to have relatively good outcome. 5, 7, 15 Nevertheless, approximately half of the AML patients lack typical prognostic karyotypic changes. To improve clinical outcome, identification of specific and accurate predictors in this group of patients by using molecular approaches is of important value.
It has been proposed that according to their roles in pathogenesis, genetic abnormalities in leukemia can be roughly grouped into two classes: mutations involving signal transduction pathways and giving rise to proliferative advantages to leukemia clones (class I), or those affecting transcription factors or co-factors and causing impaired differentiation (class II). 16 Indeed, numerous gene mutations have been discovered in AML patients without cytogenetic markers and these abnormalities have been considered to belong to either class I, as exemplified by internal tandem duplications (ITDs) or mutations of tyrosine kinase domain (TKD) of both C-KIT 17, 18 and FMS-like tyrosine kinase 3 (FLT3) genes 11, 19, 20 , and point mutations of
For personal use only. on January 1, 2018. by guest www.bloodjournal.org From neuroblastoma RAS viral oncogene homolog gene (NRAS) 17,21-24 , or to class II, such as mutations of nucleophosmin gene (NPM1) 2, 4, 22, 25 , the CCAAT/enhancer binding protein α gene (CEBPA), Wilm's tumor (WT1) gene and additional sex combs like 1 (ASXL1). [26] [27] [28] [29] [30] Recently, a new category of gene mutations associated with epigenetic regulation have drawn much attention, including the mutations of isocitrate dehydrogenase1 (IDH1), isocitrate dehydrogenase2 (IDH2) and ten eleven 2 (TET2) mutation which result in a hypermethylation phenotype with impairment of hematopoietic differentiation. [31] [32] [33] The mixed-lineage leukemia (MLL) gene, which can be affected either through chromosomal translocation or via an intragenic partial tandem duplications (PTDs) to form fusion gene, actually encodes a histone methyltransferase. 22, [34] [35] [36] Discovery of these genetic events has raised the possibility of a new class of leukemogenic genes.
Importantly, the above-mentioned molecular aberrations exert profound effects on individual response to the therapy and treatment outcome of the disease. 14,16,37 It has been described that CEBPA mutations 27, 28 and NPM1 mutations without 16, 20, 23, 25 are associated with a favorable prognosis; whereas gene mutations related with poor prognosis include C-KIT involvement among CBF AMLs 17,18,23 , FLT3-ITD without NPM1 mutations, 16, 20, 23, 25 and MLL-PTD mutations among AML with normal cytogenetics. 22, 34, 35 However, the role of leukemic IDH1 and IDH2 mutations as well as WT1, TET2 and ASXL1 mutations in predicting the prognosis of AML are not clearly established. [31] [32] [33] 38 In addition, these markers may also provide potential molecular targets for tailored therapies, as recently reported by several mutations are associated with hyperleukocytosis at disease presentation, elderly age and poor prognosis. With the accumulation of more new data, decision making of risk-stratified therapy will be possible and should be integrated into the individualized treatment of AML.
FLT3-ITD
We performed this study to systemically investigate the frequencies and the prognostic relevance of previously known genetic events and newly established molecular markers in a large series of adult AML patients. In particular, we intent to stratify the "ambiguous" AML patients who lacked cytogenetic prognostic markers into appropriate prognostic groups by using molecular markers.
Patients, materials, and methods

Patients
Bone marrow (BM) and peripheral blood (PB) samples were collected from 1,185 patients with de novo AML from 1998 to 2010 from the centers of Shanghai Institute
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French-American-British (FAB) criteria were used to define the AML subtypes (M0 through M7, with a few cases not classifiable according to the FAB nomenclature).
Patients with leukemia either transformed from myelodysplasia syndrome (MDS) or secondary to other malignancies were excluded from this study.
All the samples were assessed for overview of pattern and distribution of gene mutations, and they were further divided into three groups. Group I containing 605 cases, without prognostic cytogenetic markers except for 11q23, which represented the focus of this study for clinical relevance of gene abnormalities and prognostic analysis. This study was approved by the ethnic board of all participating centers. All patients were given informed consent for both treatment and cryopreservation of BM and PB according to the Declaration of Helsinki.
Treatment protocols
For APL (AML-M3) patients with t (15; 17), all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) based treatment was given for the induction and consolidation therapy.
14 Other AML patients received standard first line treatment of DA like regimen, which consisted of daunorubicin 45mg/m 2 , D1-3; and Ara-C 100-150mg/m 2 , D1-7. In the consolidation therapy, young patients were treated with high-dose cytarabine based chemotherapy. Due to small number of the patients (47 cases) received allogenetic stem cell transplantation (allo-SCT), they were not separated for further analysis. The chemotherapy consolidation for elderly patients was mainly decided by the physicians in an individualized manner, as previously described.
46
Cytogenetic and molecular genetic analysis
Cytogenetic and molecular studies were performed centrally in SIH and ZIH. The BM samples of de novo AML patients were studies mostly by R-and/or G-banding analysis, and were confirmed in most cases with relevant molecular markers.
Chromosomal abnormalities were described according to the International System for Human Cytogenetic Nomenclature. 
Microarray expression profiling and methylation analysis
Affymetrix Human Genome U133 Plus 2.0 Array GeneChip microarrays were used to assess the total RNA samples (Affymetrix). DNA samples were extracted for the HG18 Methylation 2.1M Deluxe Promoter Array (NimbleGen) to identify the methylated DNA regions. The procedure and statistical analysis were performed as previously reported. 40 All microarray data are available in the NCBI Gene Expression Omnibus (GEO) under accession number GSE27244.
Statistical analyses
For clinical analysis, complete remission (CR) was defined according to the 
Results
Patient characteristics
The characteristics of the 1,185 de novo AML patients are summarized in 
Correlation between gene expression levels and DNA methylation status associated with DNMT3A mutations
We previously reported that aberrant DNA methyltransferase activity due to DNMT3A mutations could change DNA methylation and alter gene expression. 40 Interestingly, through in-depth exploration of the possible consequences of the DNMT3A mutations using microarray data of expression profile and whole genomic DNA methylation, we identified a correlation between gene expression levels and the DNA methylation status in some genes. 28 up-regulated genes with DNA hypomethylation and 47 down-regulated genes accompanied with DNA For personal use only. on January 1, 2018. by guest www.bloodjournal.org From hypermethylation were revealed ( Figure 1B ). Among them, some genes were associated with hematopoiesis and epigenetics regulation, including CCDC56, DCXR, TNFSF13 and SLC25A11 (up-regulated) and SCL25A37 and EIF4G3 (down-regulated).
A correlation was revealed between the gene expression levels of CCDC56, DCXR and TNFSF13 and the mutation of DNMT3A, whereas no up-regulation of these 3 genes was observed in patients with MLL rearrangement ( Figure 1C ).
It has been reported that increased expression of multiple homeobox (HOX) genes such as HOXA7, HOXA9, HOXA10 and MEIS1 due to MLL abnormalities play an important role in leukemogenesis. 40 Recently, we demonstrated an up-regulation of HOXB family genes and IDH1 gene among patients with DNMT3A mutations in our previous work. 40 We also observed from this study that though MLL and DNMT3A mutations seldom overlapped, they shared a common feature of poor prognosis in distinct patient populations. Therefore, we tried to address possible association of expression levels of different HOX genes with MLL or DNMT3A abnormalities.
Interestingly, members of the HOXB family were found over-expressed only in a group with DNMT3A mutations, while up-regulation of MEIS1 gene could be observed only in patients with MLL abnormalities. Over-expression of HOXA7, HOXA9 and HOXA10 genes was observed in both DNMT3A and MLL abnormalities groups, contrarily to the situation of HOXA5 and HOXA13 of which the expression was not affected by DNMT3A and MLL abnormalities ( Figure 1D ). Although we previously found hypomethylation in genomic sequences of some HOXB family members, which might contribute to over-expression status of these genes 40 , this time no obvious 1 5 changes were found in HOXA family genes and the exact molecular mechanisms for their up-regulation need further investigation.
Molecular markers and clinical aspects
As far as the possible association with clinic features, we found that mutations of NPM1, CEBPA, and nearly all the epigenetics regulatory genes (DNMT3A, IDH1, IDH2 and TET2) except for MLL rearrangements were related with an elderly age at diagnosis; FLT3, NPM1, CEBPA, DNMT3A, MLL, and IDH2 mutations were related with high WBC count at presentation; and NPM1, FLT3, DNMT3A, MLL mutations were associated to a higher percentage of blasts in BM (Table 2 ).
Response to induction therapy
In univariate analysis of the 605 cases in Group I, DNMT3A mutations, MLL abnormalities and N-RAS mutations were associated with a statistically significant lower CR rate (45.8%, 48.2%, and 41.2%, P=0.014, 0.022 and 0.030 respectively) in contrast to CEBPA mutations (67.5%) which conferred a higher CR rate (P=0.030).
However, only bi-allelic (75.3%), but not mono-allelic (56.0%), CEBPA mutations were associated with favorable response to the treatment (P=0.003 and 1.000, respectively Figure 3) . Hence, according to the gene mutational status, the 605 Group I patients could be clearly classified into distinct prognostic subgroups.
Discussion
It has long been appreciated that cytogenetic factors are independent predictors for the prognosis of AML patients. 7, 8, 10, 15, 45 However, there are still more than half of AML patients in whom no cytogenetic markers can be found. Genetic mutations that escape In this study, we attempted to clarify the value of a cluster of molecular markers other than cytogenetic factors in stratification of AML patients into different prognostic groups. One important finding was that the recently reported DNMT3A mutations indeed had a higher incidence in M4 and M5 subtypes (10.0% and 18.2%, respectively, P<0.001) in a much larger patient cohort in this study. 40 The fact that DNMT3A mutations were also identified in 2 cases of M6 with erythromonocytic leukemia provides further evidence that DNMT3A mutations are restricted to the monocytic lineage involvement in AML. We also detected, for the first time, DNMT3A were also proved to be affected by DNMT3A mutation, which deserves mechanistic It is worth pointing out that abnormalities of epigenetic regulation seems to play an essential role in the pathogenesis of AML, as evidenced by the fact that DNMT3A is a DNA methyltransferase while MLL is a histone methyltransferase. In addition, IDH1, IDH2 and TET2 mutations were found to result in a DNA hypermethylation [31] [32] [33] 51 , and a group of histone methyltransferase genes, such as MLL2, UTX and SETD2, have recently been found to be mutated in hematologic malignancies. Importantly, mutations of EVI1, of which the protein product is assumed to interact with DNMT3A and DNMT3B, was recently reported to associate with poor prognosis in AML 1 , while mutations of EZH2, encoding a histone methyltransferase which could interact with DNMT3A, were described in lymphomas and MDS.
52,53
Taking into consideration of these data, we would like to make a proposal that gene mutations involved in epigenetic regulation may be considered as a third class, apart from classes I and II mutations, in that they not only belong to a distinct regulatory network but also might share common features of aggressive disease, poor prognosis and older age onset (with the exception of MLL abnormalities).
In the present study, logistic-regression analyses showed that DNMT3A mutations represented independent unfavorable prognostic factor for remission induction with conventional daunorubicin and cytarabine-based chemotherapy; in contrast, bi-allelic
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